CardioNet, Inc. Updates Full Year 2009 Guidance, Industry Dynamics and Future Strategies

Conference Call Scheduled for Wednesday, July 1, 2009 at 8:30 am
CONSHOHOCKEN, Pa.--(Business Wire)--
CardioNet (Nasdaq:BEAT), a leading wireless medical technology company with an
initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced
today an adjustment to its previously stated full year 2009 financial guidance.

The Company is revising its revenue guidance for full year 2009 to reflect
growth of 30%-33% compared to the full year 2008 and now expects revenue for
2009 to be in the range of $156 million to $160 million. The revenue guidance is
based on lower than anticipated commercial reimbursement rates. Volume growth
continues to be significant, but is expected to be somewhat lower than the
Company had anticipated. The Company believes that the long-term outlook for its
business and the wireless healthcare industry remains highly attractive, and
CardioNet intends to continue its previously announced investments in its sales
and marketing organization, product development and clinical research programs.
Other areas of spending will be curtailed and restructured to partially offset
the negative price and volume dynamics. Accordingly, the Company is now
expecting adjusted earnings per diluted share for full year 2009 to be in the
range of $0.30 to $0.35 excluding any impact of NOLs, other tax related items
and any nonrecurring charges, with the majority of the impact affecting results
in the second half of 2009. At this time, the Company is not in a position to
provide revenue or earnings guidance for 2010 and 2011. The Company may issue
such guidance if greater certainty develops with respect to long-term
reimbursement and physician adoption. CardioNet`s balance sheet remains strong
with no debt and substantial cash.

Randy Thurman, Chairman, President and Chief Executive Officer of CardioNet
said, "With nearly 250,000 patients monitored, over 200 million covered lives
and 28 completed clinical research studies, CardioNet is the unquestioned leader
in mobile cardiac outpatient telemetry. The Company continues to develop
clinically relevant product innovations, as demonstrated by the recent
introduction of SomNetTM, a new clinical indicator for common sleep disorders.
While only on the market for two weeks, CardioNet has seen over 100 physician
practices enroll in the program. Additionally, the Company just completed
training for its expanded sales organization and expects to have over 140
experienced cardiology account executives fully deployed beginning in the third
quarter of 2009. CardioNet believes this will be the largest sales organization
in the world dedicated to wireless healthcare. The second half of the year will
also be marked by the Company`s entry into the hospital and cardiac thoracic
surgery markets and by the nationwide introduction of new physician programs
aimed at accelerating the use of MCOT."

The Company also intends to expand its business base with the previously
announced acquisition of Biotel Inc., which includes the leading wireless event
monitor and accelerates development of CardioNet`s wireless MCOT technology. In
addition to giving CardioNet what the Company sees as the best array of product
technology in the industry, Biotel positions the Company to enter the clinical
research industry through Biotel`s Agility division. To illustrate the
attractiveness of this strategy, CardioNet was just selected by a major global
pharmaceutical company to provide clinical research support for drug
development. Biotel`s Agility division will accelerate growth of this attractive
source of revenue that is not directly subject to reimbursement dynamics.
Strategic and synergistic acquisitions are likely to be an important aspect of
the Company`s future.

Randy Thurman added, "Year to date our MCOT patient volume is up over 60%
compared to prior year and projected to be up over 60% for the full year. While
revenue is somewhat lower than planned, earnings will also reflect our
investments for long-term growth and the anticipated lower commercial
reimbursements rates. We believe the dynamics of robust growth in a highly cost
conscious healthcare reform market will continue long-term. As such, CardioNet
will be structured to produce long-term shareholder value in that environment.

"CardioNet is the pioneer in the field of wireless cardiac arrhythmia monitoring
and diagnosis. In contrast to healthcare technologies that have long existed, we
are in the challenging position of forecasting the future growth of a
revolutionary new technology in the midst of dramatic healthcare reform and
overwhelming pressure on costs. As we continue to build our leadership position
with MCOT, forecasting the business results will become more certain.

"We remain confident that wireless healthcare technologies will be one of the
most dramatic, revolutionary changes in human health for the next decade and
beyond. We believe that the cost benefit advantages and superior clinical
outcomes of technologies such as MCOT will prevail even in this cost driven
reimbursement environment. With our proven platform technology, expanding
wireless applications and entry into new related business segments, CardioNet,
our physicians, patients and shareholders are positioned to benefit from our
strategy over the long term."

Conference Call

CardioNet, Inc. will host an earnings conference call on Wednesday, July 1,
2009, at 8:30 AM Eastern Time. The call will be simultaneously webcast on the
investor information page of the Company`s website, www.cardionet.com. The call
will be archived on the Company`s website and will also be available for two
weeks via phone at 1-888-286-8010, access code 51216355.

CardioNet is the leading provider of ambulatory, continuous, real-time
outpatient management solutions for monitoring relevant and timely clinical
information regarding an individual's health. CardioNet's initial efforts are
focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm
disorders, with a solution that it markets as Mobile Cardiac Outpatient
TelemetryTM (MCOT). More information can be found at http://www.cardionet.com.

Forward-Looking Statements

This press release includes certain forward-looking statements within the
meaning of the "Safe Harbor" provisions of the Private Securities Litigation
Reform Act of 1995 regarding, among other things, our growth prospects, the
prospects for our products and our confidence in the Company's future. These
statements may be identified by words such as "expect," "anticipate,"
"estimate," "intend," "plan," "believe," "promises" and other words and terms of
similar meaning. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties, including important
factors that could delay, divert, or change any of them, and could cause actual
outcomes and results to differ materially from current expectations. These
factors include, among other things, the success of our sales and marketing
initiatives, our ability to attract and retain talented executive management and
sales personnel, our ability to identify acquisition candidates, acquire them on
attractive terms and integrate their operations into our business, the
commercialization of new products, market factors, internal research and
development initiatives, partnered research and development initiatives,
competitive product development, changes in governmental regulations and
legislation, changes to reimbursement levels for our products, the continued
consolidation of payors, acceptance of our new products and services and patent
protection and litigation. For further details and a discussion of these and
other risks and uncertainties, please see our public filings with the Securities
and Exchange Commission, including our latest periodic reports on Form 10-K and
10-Q. We undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise.

CardioNet, Inc.
Marty Galvan
Investor Relations
800-908-7103
investorrelations@cardionet.com

Copyright Business Wire 2009